Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909886 | 0.79 | UHRF1 (0.43) | MAPTTDP1SMN1; SMN2LIN28AHRH3 | |
| SCHEMBL20889902 | 0.79 | NOS3 (0.50) | MAPTTDP1SMN1; SMN2LIN28AHRH3 | |
| SCHEMBL14086544 | 0.78 | — | — | |
| SCHEMBL8265623 | 0.78 | ALDH1A1 (0.46) | MAPTTDP1HRH3KDM4EHTT | |
| SCHEMBL20890554 | 0.75 | KDM4E (0.42) | MAPTTDP1SMN1; SMN2LIN28AHRH3 | |
| SCHEMBL20197212 | 0.75 | KDM4E (0.53) | MAPTKDM4EPOLBALDH1A1RECQL | |
| SCHEMBL2983577 | 0.74 | — | — | |
| SCHEMBL13382314 | 0.73 | SIRT2 (0.43) | MAPTTDP1SMN1; SMN2LIN28AKDM4E | |
| SCHEMBL21610450 | 0.71 | — | — | |
| SCHEMBL29877048 | 0.71 | TDP1 (0.70) | MAPTTDP1SMN1; SMN2LIN28AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1765264-B1 | DENTAL COMPOSITION CONTAINING UNSATURATED CARBOSILANE CONTAINING COMPONENTS | MINNESOTA MINING MFG GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| CN-101128461-B | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI | 2010-12-22 | — | — | CN | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7662869-B2 | Curable di- or polyunsaturated carbosilane containing silicon-aryl bondand no silicon-oxygen bonds; initiator, filler, dyes, pigments, thixotropic agents, flow control agents, polymeric thickeners, surfactants, odorous substances, diluting agent(s) and flavors; crowns, bridges | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070193-A1 | Dental Composition Containing Unsaturated Carbosilane Containing Components | 3M DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| CN-101128461-A | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1765264-A1 | DENTAL COMPOSITION CONTAINING UNSATURATED CARBOSILANE CONTAINING COMPONENTS | 3M Espe AG (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006005368-A1 | DENTAL COMPOSITION CONTAINING UNSATURATED CARBOSILANE CONTAINING COMPONENTS | 3M ESPE AG (DE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | MAPT 3986/4885TDP1 3237/4885SMN1; SMN2 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.